PDB-code
Browse PDE entries (page 19 of 31)
First 15 16 17 PreviousLast23 22 21 Next| # | Species | PDE Type | PDB | Chain | Alternate Model | Ligand | Details | File |
|---|---|---|---|---|---|---|---|---|
 | Human | PDE4B | 3wd9 | A | 4-[(4-{2-[(2,2-dimethylpropyl)amino]-2-oxoethyl}phenyl)amino]-2-phenylpyrimidine-5-carboxamide |  | ||
| Human | PDE4B | 3wd9 | B | 4-[(4-{2-[(2,2-dimethylpropyl)amino]-2-oxoethyl}phenyl)amino]-2-phenylpyrimidine-5-carboxamide | | ||
| Human | PDE4B | 4kp6 | A | A | 2-ethyl-2-{[4-(methylamino)-6-(1H-1,2,4-triazol-1-yl)-1,3,5-triazin-2-yl]amino}butanenitrile | | |
| Human | PDE4B | 4kp6 | A | B | 2-ethyl-2-{[4-(methylamino)-6-(1H-1,2,4-triazol-1-yl)-1,3,5-triazin-2-yl]amino}butanenitrile | | |
| Human | PDE4B | 4myq | A | A | (4-{[2-(5-chlorothiophen-2-yl)-5-ethyl-6-methylpyrimidin-4-yl]amino}phenyl)aceticacid | | |
| Human | PDE4B | 4myq | A | B | (4-{[2-(5-chlorothiophen-2-yl)-5-ethyl-6-methylpyrimidin-4-yl]amino}phenyl)aceticacid | | |
| Human | PDE4B | 4nw7 | A | A | (4-{[4-(3-chlorophenyl)-6-cyclopropyl-1,3,5-triazin-2-yl]amino}phenyl)aceticacid | | |
| Human | PDE4B | 4nw7 | A | B | (4-{[4-(3-chlorophenyl)-6-cyclopropyl-1,3,5-triazin-2-yl]amino}phenyl)aceticacid | | |
| Human | PDE4B | 4wzi | A | A | | ||
| Human | PDE4B | 4wzi | A | B | | ||
| Human | PDE4B | 4wzi | B | A | | ||
| Human | PDE4B | 4wzi | B | B | | ||
| Human | PDE4B | 4x0f | A | ROLIPRAM | | ||
| Human | PDE4B | 4x0f | B | ROLIPRAM | | ||
| Human | PDE4B | 5k6j | A | A | 6-[[7,7-bis(oxidanyl)-8-oxa-7-boranuidabicyclo[4.3.0]nona-1(6),2,4-trien-3-yl]oxy]-5-chloranyl-2-(4-oxidanylidenepentoxy)pyridine-3-carbonitrile | | |
| Human | PDE4B | 5k6j | A | B | 6-[[7,7-bis(oxidanyl)-8-oxa-7-boranuidabicyclo[4.3.0]nona-1(6),2,4-trien-3-yl]oxy]-5-chloranyl-2-(4-oxidanylidenepentoxy)pyridine-3-carbonitrile | | |
| Human | PDE4B | 5ohj | A | A | [(1~{S})-2-[3,5-bis(chloranyl)-1-oxidanyl- pyridin-1-ium-4-yl]-1-[4-[bis(fluoranyl)methoxy]- 3-(cyclopropylmethoxy)phenyl]ethyl] (2~{S})- 1-[3-(dimethylcarbamoyl)phenyl]sulfonylpyrrolidine- 2-carboxylate | | |
| Human | PDE4B | 5ohj | A | B | [(1~{S})-2-[3,5-bis(chloranyl)-1-oxidanyl- pyridin-1-ium-4-yl]-1-[4-[bis(fluoranyl)methoxy]- 3-(cyclopropylmethoxy)phenyl]ethyl] (2~{S})- 1-[3-(dimethylcarbamoyl)phenyl]sulfonylpyrrolidine- 2-carboxylate | | |
| Human | PDE4B | 5ohj | B | A | [(1~{S})-2-[3,5-bis(chloranyl)-1-oxidanyl- pyridin-1-ium-4-yl]-1-[4-[bis(fluoranyl)methoxy]- 3-(cyclopropylmethoxy)phenyl]ethyl] (2~{S})- 1-[3-(dimethylcarbamoyl)phenyl]sulfonylpyrrolidine- 2-carboxylate | | |
| Human | PDE4B | 5ohj | B | B | [(1~{S})-2-[3,5-bis(chloranyl)-1-oxidanyl- pyridin-1-ium-4-yl]-1-[4-[bis(fluoranyl)methoxy]- 3-(cyclopropylmethoxy)phenyl]ethyl] (2~{S})- 1-[3-(dimethylcarbamoyl)phenyl]sulfonylpyrrolidine- 2-carboxylate | | |
| Human | PDE4C | 2qym | A | | |||
| Human | PDE4D | 1mkd | A | 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE | | ||
| Human | PDE4D | 1mkd | B | 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE | | ||
| Human | PDE4D | 1mkd | C | 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE | | ||
| Human | PDE4D | 1mkd | D | 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE | | ||
| Human | PDE4D | 1mkd | E | 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE | | ||
| Human | PDE4D | 1mkd | F | 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE | | ||
| Human | PDE4D | 1mkd | G | 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE | | ||
| Human | PDE4D | 1mkd | H | 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE | | ||
| Human | PDE4D | 1mkd | I | 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE | |
This research was performed as part of the "Phosphodiesterase inhibitors for neglected parasitic diseases" (PDE4NPD) programme, which is supported by the European Union 7th Framework Program (FP7/2007-2013) under grant agreement n° 602666.
